Akebia Therapeutics Inc. (NASDAQ:AKBA) traded at $1.32 at close of the session on Monday, April 29, made a downward move of -1.49% on its previous day’s price.
Looking at the stock we see that its previous close was $1.34. In terms of its 52-week price range, AKBA has a high of $2.48 and a low of $0.78. The company’s stock has lost about -27.87% over that past 30 days.
Akebia Therapeutics Inc. has a market cap of $276.37 million. Estimates by analysts give the company expected earnings per share (EPS) of -$0.08, with the EPS growth for the year raised at -$0.29 for 2024 and -$0.32 for next year. These figures represent -3.60% and -10.30% growth in EPS for the two years respectively.
Analysts tracking the company’s growth have also given it a consensus growth in revenue estimated at $46.09 million, with a low of $40.1 million and a high of $56 million. The median projection represents growth squeezing down to 14.90% compared to sales growth for the corresponding quarter a year ago. According to analyst consensus estimates figures, the company’s yearly revenue forecast for 2024 is expected to hit $188.51 million, or -3.10% down from figures reported last year.
On the other hand, looking at the outlook for the AKBA stock, short term indicators assign the stock an average of 50% Sell, while medium term indicators assign it an average of 50% Buy. Long term indicators on average place the stock in the category of Hold.
Looking further, we note the current price level is -9.03% off its SMA20 and -16.08% from its 50-day simple moving average. The RSI (14) is pointing at 36.64 while the volatility over the past week is 4.24% and jumps to 7.18% over the past one month. The beta value is 0.90, while the average true range (ATR) is currently pointing at 0.12.
Coming back to Akebia Therapeutics Inc. (NASDAQ:AKBA), we note that the average 3-month trading volume was 4.84 million. Current shares outstanding are 194.58 million.
The insiders hold 10.84% of the company’s shares while institutions hold 18.81%. Investors should be excited about this stock as its upside potential is great, with current price pushing the stock 6.45% up in year-to-date price movement.
